Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Posterior subcapsular lens opacities" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Ocular solutions
InactiveUS7083803B2Reduce inflammationReduce bacterial growthBiocideSenses disorderDiseaseEverolimus
Ocular solutions containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease.
Owner:PEYMAN GHOLAM A DR
Intraocular Lens Cell Migration Inhibition System
InactiveUS20120232649A1Inhibit migrationReduce posterior capsule opacificationEye treatmentTissue regenerationPosterior capsular opacificationLens epithelial cell
Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.
Owner:INSIGHT INNOVATIONS
Methods for preventing or treating posterior capsular opacification
InactiveUS20160106591A1Preventing and treatingNot to damageLaser surgerySurgical instrument detailsPosterior capsule opacificationRectal epithelium
The present invention relates to methods and apparatus for preventing or treating posterior capsular opacification in a subject in need of prophylaxis or treatment for posterior capsular opacification, including a subject undergoing cataract surgery by ablating epithelial cells on an interior surface of the lens capsule with a multi-photon laser system.
Owner:NEXXTVISIONLLC
Ocular solutions
InactiveUS7087237B2Reduce inflammationReduce bacterial growthAntibacterial agentsBiocideEverolimusMacrolide resistance
Containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.
Owner:PEYMAN GHOLAM A DR
Intraocular implant cell migration inhibition system
InactiveUS20110295367A1Inhibit migrationReduce posterior capsule opacificationEye surgeryTissue regenerationPosterior capsular opacificationLens epithelial cell
Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.
Owner:INSIGHT INNOVATIONS
Nanometer fluorouracil coat artificial crystalloid and the preparing method
InactiveCN101036804ASuppress turbidityLow toxicityCoatingsIntraocular lensPosterior capsule opacificationChitosan nanoparticles
The invention relates to a intraocular lens. At present the Poly-Methyl Methacrylate (PMMA) intraocular lens conventional for clinical treatment of cataract always causes inflammatory treaction after implantation. Posterior capsule opacification is also a major compalication after cataract surgery. The invention selects fluorouracil to solve the above problems. Based on weak penetrating force of chitosan nanoparticles in eyes and the relation between the phagocytosis amount of conjunctival epithelial cells to nanoparticles and the particle size of nanoparticles, the fluorouracil nanoparticles preparation is prepared using chitosan-poly(acrylic acid) as carrier, composite coated on the surface of PMMA intraocular lens. The invantion also provides a preparation method thereof. The said intraocular lens not only increases the biocompatibility of the intraocular lens, but also inhibites posterior capsule opacification pafter cataract surgery. The said intraocular lens can also prevent anterior membrane after implantation of intraocular lens and after-cataract.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Micropatterned Intraocular Implant
InactiveUS20150342725A1Inhibit migrationInhibit growth and migrationTissue regenerationIntraocular lensPosterior capsule opacificationLens epithelial cell
Generally, an intraocular implant having on the external surface a plurality of pattern surface elements disposed in spaced apart relation defining a tortuous pathway adapted to control a flow of fluid, or a flow of particles suspended in a fluid, or inhibits the growth or migration of cells. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits growth or migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.
Owner:SHARKLET TECH +2
Treatment Solution and Method for Preventing Posterior Capsular Opacification by Selectively Inducing Detachment And/Or Death of Lens Epithelial Cells
InactiveUS20070129286A1Great incidencePrevent PCOBiocideSenses disorderIon distributionCellular mechanism
A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.
Owner:ABBOTT MEDICAL OPTICS INC
Intraocular Lens Cell Migration Inhibition System
ActiveUS20130304205A1Inhibit migrationReduce posterior capsule opacificationEye treatmentTissue regenerationPosterior capsular opacificationLens epithelial cell
Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.
Owner:INSIGHT INNOVATIONS
System and Method for Obviating Posterior Capsule Opacification
InactiveUS20130103012A1Avoid potential damageAppropriate distanceLaser surgerySurgical instrument detailsPosterior capsule opacificationFemto second laser
A system and method are provided for obviating Posterior Capsule Opacification (PCO) which require an Optical Coherence Tomography (OCT) device for imaging the interface surface between the posterior surface of an intraocular lens (IOL) and the capsular bag. Further, the OCT device is used to identify areas of relative opacity caused by a biological growth on the interface surface in the optical zone of the IOL. A laser unit is then used to direct the focal point of a femtosecond laser beam onto the areas of relative opacity to ablate the biological growth by Laser Induced Optical Breakdown (LIOB) to thereby obviate the PCO.
Owner:BAUSCH & LOMB INC
Posterior chamber intraocular lens
ActiveUS20140358225A1Increase spacingPromote lowerIntraocular lensPosterior capsule opacificationAnterior surface
The present invention relates to a posterior chamber intraocular lens (IOL), comprising: an optic consisting of an effective optical area and an effective optical area edge; at least two haptics connected to the optic, wherein a posterior surface of the effective optical area is a convex surface, and a basic spherical surface thereof has a radius of curvature in a range of 6.6 mm-80.0 mm. The effective optical area of the posterior chamber IOL adopts a design with the posterior surface obviously convex, which reduces the distance between the posterior surface of the effective optical area of the IOL and the posterior capsule, improves the stability of a spatial position of the IOL in a capsule bag, and reduces an incidence rate of posterior capsule opacification (PCO) after implantation of the IOL; since the effective optical area anterior surface is relatively flat, the IOL haptics will not be tightly pressed on the effective optical area anterior surface upon folding, the haptics are more easily unfolded after implantation into the eye and the support haptics are not mutually adhered to the effective optical area, and meanwhile the IOL imaging quality can be improved and / or the visual quality of the astigmatism sufferer is enhanced.
Owner:EYEBRIGHT MEDICAL TECH BEIJING
Method For The Treatment Of Proliferative Disorders Of The Eye
InactiveUS20110200662A1Inhibit cell proliferationLarge therapeutic indexBiocideSenses disorderUveitisMelanoma
The present invention relates to method for the treatment or prevention and of proliferative eye diseases including but not limited to: age related macular degeneration associated proliferative retinopathy, proliferative diabetic retinopathy, proliferative vitreoretinopathy, posterior capsular opacification, scaring and fibrosis after glaucoma filtration surgery, uveal melanoma, and retinoblastoma. The method comprises contacting cells in the eye by means of intra-ocular injection or infusion, with a drug that irreversibly inhibits cellular proliferation without causing extensive tissue necrosis or cytotoxicity. In a preferred embodiment the drug is bizelesin.
Owner:ONCOTX
Intraocular implant cell migration inhibition system
InactiveUS8551167B2Inhibit migrationReduce posterior capsule opacificationEye surgeryTissue regenerationPosterior capsular opacificationLens epithelial cell
Owner:INSIGHT INNOVATIONS
Cell Migration Inhibition System
InactiveUS20140288645A1Inhibit migrationReduce posterior capsule opacificationEye treatmentTissue regenerationPosterior capsular opacificationLens epithelial cell
Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.
Owner:INSIGHT INNOVATIONS
Artificial crystalline lens used for preventing and treating posterior capsule opacification and preparation method thereof
The invention discloses an artificial crystalline lens used for preventing and / or treating posterior capsule opacification and a preparation method of the artificial crystalline lens. Trypsin is fixed on the surface of the artificial crystalline lens, namely the trypsin which has a lethal effect on crystalline lens epithelial cells is fixed on the surface of the artificial crystalline lens. Therefore, the artificial crystalline lens can selectively destroy the crystalline lens epithelial cells in a lens capsule when the artificial crystalline lens is transplanted into the lens capsule. Occurring of posterior capsular opacification is avoided.
Owner:BEIJING TONGREN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
InactiveUS7875270B2Great incidencePrevent PCOSenses disorderHydroxy compound active ingredientsIon distributionLens placode
A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.
Owner:ZHANG JIN JUN
Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
InactiveUS20050159410A1Prevent PCOEasy to disassembleSenses disorderHydroxy compound active ingredientsIon distributionCellular mechanism
A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.
Owner:ZHANG JIN JUN
Hydrodissection and posterior capsule opacification prevention during capsulotomy procedure
ActiveUS20190231593A1PCO prevention and reductionEasy to disassembleLaser surgerySurgical instruments for heatingPosterior capsule opacificationCapsulotomy
Embodiments of the invention provide hydrodissection and / or PCO prevention or reduction in a patient undergoing eye surgery. In one embodiment, the invention is a surgical device for cutting and excising a portion of tissue, for example in performing a lens capsulotomy. A capsulotomy tip is inserted into an eye through an incision in the surface of the eye. The capsulotomy tip includes a suction cup to provide suction to the lens capsule. Then suction is applied via the suction cup to secure the capsulotomy tip to the eye. In some embodiments, after the capsulotomy tip is secured to the lens capsule, a cutting element of the capsulotomy tip is used to cut a tissue of the eye. Fluid is pushed through the capsulotomy tip and the capsulotomy tip is removed from the eye. Moreover, disclosed is an intraocular lens (IOL) to be used in conjunction with the surgical device.
Owner:MYNOSYS CELLULAR DEVICES INC
Application of pirfenidone in preparation of medicaments for controlling proliferative diseases after ophthalmologic operation and eye drops thereof
ActiveCN102349901AImprove stabilityInhibit migrationOrganic active ingredientsBlood disorderPosterior capsule opacificationSide effect
The invention discloses an application of pirfenidone in the preparation of medicaments for controlling proliferative diseases after an ophthalmologic operation and eye drops thereof. According to the invention, pirfenidone is prepared into the eye drops. Experiments show that pirfenidone has good stability and good ocular tissue permeability, can inhibit HLECs migration and propagation, and has no cytotoxicity to HLECs within the action range (0-1mg / ml). With pirfenidone being within the range of 0-1%, the eye drops are continuously applied on eyes within a month with safety and with no obvious toxic and side effect. Pirfenidone can be used to delay the generation of PCO after the rabbit corneal Phaco operation, reduce HLECs propagation and minimize the shield of PCO to an optical region. In addition, there is no obvious ocular surface injury or postoperative inflammation aggravation and severe adverse reaction after PFD is applied in the rabbit corneal Phaco operation. Therefore, pirfenidone can be used to control proliferative diseases after an ophthalmologic operation, especially posterior capsule opacification generated after a cataract surgery.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
Accommodative intraocular lens that ejects post capsular opacification and self-centers
ActiveUS20180104047A1Reduces potential warpageGood removal effectIntraocular lensPosterior capsule opacificationAnterior surface
Described is an accommodating intraocular lens with a bi-convex, bi-aspheric, smooth surfaced optic held inside an anterior annulus via tabs. A second larger diameter annulus is positioned posteriorly and connects via a sloped surface to where the annuluses are at a maximum separation when viewing NEAR objects and minimum separation in the FAR position. The sloped surface is cut into ribbons, tabs and / or other annuluses without pushing the surfaces into the capsule when implanted; therefore, only the anterior and posterior annuluses have a force component against the capsule. The proximal edge of the anterior annulus is anterior to the apex of the anterior surface of the optic. The anterior capsule resting on the annulus leaves space for hydration of the capsule and reduces potential warpage of the optic. The annulus edge is designed to scrape posterior capsular opacification from the capsule.
Owner:CALLAHAN WAYNE B
Intraocular lenses with interlenticular opacification resistance
InactiveUS20120059466A1Avoid turbidityPharmaceutical containersPretreated surfacesPosterior capsule opacificationIntraocular lens
The present invention is directed to an intraocular lens, an intraocular lens system and a method of producing and / or implanting the lens or system in an eye wherein at least one intraocular lens includes a coating that aids in resisting opacification (e.g., posterior capsule opacification (PCO), interlenticular opacification (ILO) or the like). The material of the coating is preferably hydrophilic or super-hydrophobic.
Owner:NOVARTIS AG
A kind of intraocular lens for prevention and treatment of after cataract and preparation method thereof
The invention discloses an artificial crystalline lens used for preventing and / or treating posterior capsule opacification and a preparation method of the artificial crystalline lens. Trypsin is fixed on the surface of the artificial crystalline lens, namely the trypsin which has a lethal effect on crystalline lens epithelial cells is fixed on the surface of the artificial crystalline lens. Therefore, the artificial crystalline lens can selectively destroy the crystalline lens epithelial cells in a lens capsule when the artificial crystalline lens is transplanted into the lens capsule. Occurring of posterior capsular opacification is avoided.
Owner:BEIJING TONGREN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Application of pirfenidone in preparation of medicaments for controlling proliferative diseases after ophthalmologic operation and eye drops thereof
ActiveCN102349901BImprove stabilityInhibit migrationOrganic active ingredientsPosterior capsule opacificationSide effect
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
Posterior chamber intraocular lens
ActiveUS9855136B2Increase spacingPromote lowerIntraocular lensPosterior capsule opacificationImaging quality
The present invention relates to a posterior chamber intraocular lens (IOL), comprising: an optic consisting of an effective optical area and an effective optical area edge; at least two haptics connected to the optic, wherein a posterior surface of the effective optical area is a convex surface, and a basic spherical surface thereof has a radius of curvature in a range of 6.6 mm-80.0 mm. The effective optical area of the posterior chamber IOL adopts a design with the posterior surface obviously convex, which reduces the distance between the posterior surface of the effective optical area of the IOL and the posterior capsule, improves the stability of a spatial position of the IOL in a capsule bag, and reduces an incidence rate of posterior capsule opacification (PCO) after implantation of the IOL; since the effective optical area anterior surface is relatively flat, the IOL haptics will not be tightly pressed on the effective optical area anterior surface upon folding, the haptics are more easily unfolded after implantation into the eye and the support haptics are not mutually adhered to the effective optical area, and meanwhile the IOL imaging quality can be improved and / or the visual quality of the astigmatism sufferer is enhanced.
Owner:EYEBRIGHT MEDICAL TECH BEIJING
Method for reducing the risk of posterior capsular opacification
InactiveUS20060271062A1Easy to disassemblePrevent proliferationEye surgeryTissue regenerationPosterior capsule opacificationLens epithelial cell
It is disclosed here that actin-disrupting compounds and 1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine can be used to facilitate the removal of lens epithelial cells from the lens capsule during cataract surgery and they may also be used to inhibit lens epithelial cells' proliferation and / or migration after surgery to reduce the risk or severity of posterior capsular opacification. Various related methods, kits, and ocular implants for reducing the risk or severity of posterior capsular opacification are provided.
Owner:WISCONSIN ALUMNI RES FOUND
Intraocular lens with concentric ring pattern and surface modified by degradable drug sustained-release coating and preparation method of intraocular lens with concentric ring pattern and surface modified by degradable drug sustained-release coating
PendingCN113413237AAvoid complicationsAvoid turbidityMedical devicesIntraocular lensOphthalmology departmentIntraocular inflammation
The invention relates to the field of medical implant materials and instrument surface modification in the ophthalmology department, in particular to a foldable intraocular lens with a concentric ring pattern, drug sustained release function and a surface modified by a degradable drug sustained-release coating, and a preparation method of the foldable intraocular lens. The degradable drug sustained-release coating with the concentric ring pattern is formed by spin-coating a sustained-release drug composition on the surface of the intraocular lens, and the sustained-release drug composition comprises a degradable polymer, a drug and an organic solvent. The spin-coating technology is applied, the drug sustained-release coating has the special concentric ring pattern with the thin center and the thick periphery, the influence on refraction, stability and foldability of the intraocular lens is small, and the drug sustained-release coating is not prone to falling off and can be stably attached to the surface of the intraocular lens, through drug reasonable selection, the intraocular lens can be used for effectively preventing various common complications after cataract phacoemulsification surgery, such as posterior capsular opacity, intraocular inflammation and other postoperative inflammatory reactions, and the surgery effect is guaranteed.
Owner:WENZHOU MEDICAL UNIV
Accommodative intraocular lens that ejects post capsular opacification and self-centers
InactiveUS10441410B2Reduces potential warpage of the opticGood removal effectIntraocular lensPosterior capsular opacificationAnterior surface
Described is an accommodating intraocular lens with a bi-convex, bi-aspheric, smooth surfaced optic held inside an anterior annulus via tabs. A second larger diameter annulus is positioned posteriorly and connects via a sloped surface to where the annuluses are at a maximum separation when viewing NEAR objects and minimum separation in the FAR position. The sloped surface is cut into ribbons, tabs and / or other annuluses without pushing the surfaces into the capsule when implanted; therefore, only the anterior and posterior annuluses have a force component against the capsule. The proximal edge of the anterior annulus is anterior to the apex of the anterior surface of the optic. The anterior capsule resting on the annulus leaves space for hydration of the capsule and reduces potential warpage of the optic. The annulus edge is designed to scrape posterior capsular opacification from the capsule.
Owner:CALLAHAN WAYNE B
Micropatterned intraocular implants
InactiveUS20180228600A1Reduce travel requirementsFix and reduce travelEye treatmentTissue regenerationPosterior capsule opacificationIntraocular lens
Generally, an intraocular implant having on the external surface a plurality of pattern surface elements disposed in spaced apart relation defining a tortuous pathway adapted to control a flow of fluid or a flow of particles suspended in a fluid or inhibit the growth or migration of cells is provided. In particular, an intraocular implant that is implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits growth or migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.
Owner:UNIV OF FLORIDA RES FOUNDATION INC +2
Intraocular lens preventing posterior capsular opcaification and glare and preparation method thereof
ActiveCN109303625AEasy to operateReduce processing timeIntraocular lensPosterior capsular opacificationMedicine
The invention relates to the technical field of intraocular lenses, and provides an intraocular lens preventing posterior capsular opcaification and glare and a preparation method thereof. The intraocular lens has a special edge structure and a frosted side face, by means of the special edge structure, the phenomenon that lens epithelial cells grow along the rear surface of an optical region can be reduced, and then the after cataract occurrence rate is lowered; by means of the frosted side face, the occurrence rate of glare occurring after the intraocular lens is implanted in an eye can be greatly lowered.
Owner:DONGGUAN HEC MEDICAL INTELLIGENT DEVICE R&D CO LTD
Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
InactiveUS20110118174A1Great incidencePrevent PCOAntibacterial agentsBiocideIon distributionLens placode
A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.
Owner:ZHANG JINJUN
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com